Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

By Zacks Investment ResearchStock MarketsApr 15, 2019 10:54PM ET
www.investing.com/analysis/qiagen-drives-molecular-diagnostics-suite-with-new-test-kit-200407284
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
By Zacks Investment Research   |  Apr 15, 2019 10:54PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

QIAGEN N.V. (NYSE:QGEN) has unveiled its latest therascreen FGFR RGQ RT-PCR Kit (therascreen FGFR Kit) in the United States. This kit will be used as a companion diagnostic to identify patients eligible for the treatment with Janssen Biotech’s fibroblast growth factor receptor (FGFR) kinase inhibitor drug, Balversa.

The test will help detect patients with urothelial cancer, whose tumors consist of certain alterations in the fibroblast growth factor receptor 3 (FGFR3) gene.

With this launch, QIAGEN’s molecular diagnostics portfolio is likely to get a substantial boost.

Notably, the company is optimistic about the introduction of this new therascreen FGFR Kit as it is the first companion diagnostic test to have received an FDA approval for spotting FGFR gene alterations. This will help in guiding therapy in any cancer identification.

Urothelial Cancer: A Glimpse

Per the definition provided by Canadian Cancer Society, urothelial cancer or carcinoma (also known as transitional cell carcinoma) is a cancerous tumor of the bladder that can spread (metastasize) to other parts of the body. This type of cancer starts in tissues lining the bladder and other genitourinary organs and is ranked sixth among the most common cancer types in the United States.

According to a recent Grand View research article, this particular type of cancer has been considered the ninth most common malignancy with nearly 2.5 million global patients and 420,000 newly diagnosed cases registered each year.

The global urothelial cancer drug market is currently holding great prospects and is expected to reach $3.6 billion by 2023 at a CAGR of 22.9% from 2018 to 2023.

A View of Therascreen FGFR RGQ RT-PCR Kit

This new diagnostic has been designed to specifically detect the tumors with certain alterations in the fibroblast growth factor receptor 3 (FGFR3) gene. This test will be used alongside QIAGEN’s Rotor-Gene Q MDx automation solution — a kit that examines a patient’s DNA or ribonucleic acid (RNA).

A certain percentage of urothelial carcinoma tumors, having specific FGFR alterations, might be the key drivers of tumor growth. This companion diagnostic by QIAGEN will ensure easy detection of these alterations in the patients eligible for treatment with Balversa. This test will help in the guidance of treatment decisions associated with urothelial cancer and in the process, acknowledge a large percentage of the unmet medical need of the affected patients.

Market Potential

Molecular diagnostics is an area gaining a steady momentum and holding great prospects to experience rapid growth in the coming years. Going by Go Molecular reports, molecular diagnostic tests detect particular sequences in DNA or RNA that may or may not be related to disease and comprise single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, etc.

Per a report by Grand View Research, the global molecular diagnostics market size is anticipated to attain a value of $19.8 billion by 2026 witnessing a CAGR of 9.1% over the forecast period. Rising infections like human papillomavirus and influenza are the primary factors driving the market.

The addition of this diagnostic is expected to broaden QIAGEN’s molecular diagnostic segment, which is one of the four customer classes for sample and assay technologies.

QIAGEN’s Molecular Diagnostics Update

QIAGEN currently provides one of the broadest portfolios of molecular technologies for human healthcare, acknowledging significant market opportunities.

In the context of enhancing this segment, the partnership with Tecan Group to boost the processing of QIAGEN’s QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test deserves special mention. (Read more: QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test).

Zacks Rank and Share Price Movement

QIAGEN has a Zacks Rank #2 (Buy). Year to date, shares of the company have outperformed its industry. The stock has rallied 17.4% compared with the industry’s growth of 8.4%. The current level is also higher than the S&P 500 Index’s 15.4% increase.



Other Key Picks

Investors interested in other top-ranked stocks from the broader medical space can also consider ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) , Advaxis, Inc. (NASDAQ:ADXS) and DENTSPLY SIRONA Inc. (NASDAQ:XRAY) .

ANI Pharmaceuticals has an earnings growth rate of 30.9% for the next quarter. The company sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Advaxis has an earnings growth rate of 61.8% for the next quarter. The company has a Zacks Rank of 1.

DENTSPLY SIRONA has a long-term earnings growth rate of 9.6%. The company carries a Zacks Rank of 2.

Will you retire a millionaire?

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”

Click to get it free >>



Advaxis, Inc. (ADXS): Free Stock Analysis Report

QIAGEN N.V. (QGEN): Free Stock Analysis Report

ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

Original post

Zacks Investment Research
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
 

Related Articles

David Moenning
Market Is Rethinking The Outlook By David Moenning - Jan 18, 2022

From my seat, the key driver to the current action in the stock market remains the spike in bond yields. This morning's early dance to the downside represents an exclamation point...

QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email